The estimated Net Worth of Richard T Allen is at least $2.24 Milion dollars as of 3 October 2017. Richard Allen owns over 823,125 units of BioCardia stock worth over $2,238,900 and over the last 7 years Richard sold BCDA stock worth over $0.
Sign up
Richard Allen BCDA stock SEC Form 4 insiders trading
Richard has made over 1 trades of the BioCardia stock since 2017, according to the Form 4 filled with the SEC. Most recently Richard exercised 823,125 units of BCDA stock worth $123,469 on 3 October 2017.
The largest trade Richard's ever made was exercising 823,125 units of BioCardia stock on 3 October 2017 worth over $123,469. On average, Richard trades about 411,563 units every 0 days since 2017. As of 3 October 2017 Richard still owns at least 823,125 units of BioCardia stock.
You can see the complete history of Richard Allen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Richard Allen's mailing address?
Richard's mailing address filed with the SEC is 125 Shoreway Rd, San Carlos, CA 94070, USA.
Insiders trading at BioCardia
Over the last 8 years, insiders at BioCardia have traded over $2,555,815 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer oraz Richard M Krasno. On average, BioCardia executives and independent directors trade stock every 48 days with the average trade being worth of $1,321,186. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 19 January 2024, trading 129,802 units of BCDA stock currently worth $55,815.
What does BioCardia do?
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
What does BioCardia's logo look like?
Complete history of Richard Allen stock trades at BioCardia
BioCardia executives and stock owners
BioCardia executives and other stock owners filed with the SEC include:
-
Peter Altman,
President, Chief Executive Officer, Director -
Henricus Duckers,
Chief Medical Officer -
David McClung,
Chief Financial Officer -
Dr. Peter A. Altman,
CEO, Pres & Director -
David McClung,
Chief Financial Officer -
Phil Pesta,
Vice President - Operations -
Richard Krasno,
Independent Director -
Simon Stertzer,
Independent Chairman of the Board -
Richard Pfenniger,
Independent Director -
Jay Moyes,
Independent Director -
Fernando Fernandez,
Independent Director -
Andrew Blank,
Independent Director -
Jim Allen,
Independent Director -
Dr. Sujith Shetty,
Chief Medical Officer and VP of Clinical & Regulatory -
Edward M. Gillis,
Sr. VP of Devices -
Dr. Ian McNiece Ph.D.,
Chief Scientific Officer -
Allan R Tessler,
Director -
Richard T Allen,
Vice President of Quality -
Thomas Quertermous,
Director -
Eric Duckers,
Chief Medical Officer -
Phillip Md Et Al Frost Gamm...,